RU2013130002A - Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками - Google Patents
Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками Download PDFInfo
- Publication number
- RU2013130002A RU2013130002A RU2013130002/10A RU2013130002A RU2013130002A RU 2013130002 A RU2013130002 A RU 2013130002A RU 2013130002/10 A RU2013130002/10 A RU 2013130002/10A RU 2013130002 A RU2013130002 A RU 2013130002A RU 2013130002 A RU2013130002 A RU 2013130002A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antibody
- apoe
- amino acid
- atcc
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000013918 Apolipoproteins E Human genes 0.000 claims abstract 10
- 108010025628 Apolipoproteins E Proteins 0.000 claims abstract 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 208000024891 symptom Diseases 0.000 claims abstract 5
- 239000002773 nucleotide Substances 0.000 claims abstract 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 2
- 210000004408 hybridoma Anatomy 0.000 claims abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000010483 emotional dysregulation Effects 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41906010P | 2010-12-02 | 2010-12-02 | |
| US61/419,060 | 2010-12-02 | ||
| US201161548542P | 2011-10-18 | 2011-10-18 | |
| US61/548,542 | 2011-10-18 | ||
| PCT/US2011/063121 WO2012075422A2 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013130002A true RU2013130002A (ru) | 2015-01-10 |
Family
ID=46172597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013130002/10A RU2013130002A (ru) | 2010-12-02 | 2011-12-02 | Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20140037638A1 (enExample) |
| EP (1) | EP2646053A4 (enExample) |
| JP (1) | JP2014502276A (enExample) |
| KR (1) | KR20140017513A (enExample) |
| CN (1) | CN103338786A (enExample) |
| AU (1) | AU2011336360A1 (enExample) |
| BR (1) | BR112013013723A2 (enExample) |
| CA (1) | CA2819679A1 (enExample) |
| MX (1) | MX2013006116A (enExample) |
| NZ (1) | NZ611614A (enExample) |
| RU (1) | RU2013130002A (enExample) |
| SG (1) | SG190952A1 (enExample) |
| WO (1) | WO2012075422A2 (enExample) |
| ZA (1) | ZA201303996B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| BR112017006419A2 (pt) | 2014-09-30 | 2017-12-19 | Univ Washington | medições cinéticas de tau |
| EP3452074A4 (en) * | 2016-05-03 | 2019-12-11 | University of South Florida | COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN |
| US11124562B2 (en) | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
| CA3070100A1 (en) * | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type iii domains and methods of using the same |
| CN120098122A (zh) * | 2019-05-28 | 2025-06-06 | 总医院公司 | Apoe抗体、融合蛋白及其用途 |
| WO2023069892A1 (en) * | 2021-10-19 | 2023-04-27 | Short Jay M | Conditionally active proteins for neurodegenerative diseases |
| AU2023399623A1 (en) * | 2022-11-30 | 2025-07-03 | Bio-Techne Corporation | Natural killer cell engagers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI951701L (fi) * | 1992-10-13 | 1995-04-10 | Univ Duke | Menetelmät Alzheimerin taudin tunnistamiseksi |
| AR047729A1 (es) * | 2003-11-28 | 2006-02-15 | Astrazeneca Ab | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) |
| AU2005228764A1 (en) * | 2004-03-30 | 2005-10-13 | Renomedix Institute Inc. | Remedy for prion disease and method of producing the same |
| EP1991252A2 (en) * | 2006-02-21 | 2008-11-19 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| AU2007332473B2 (en) * | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| US9102717B2 (en) * | 2010-03-01 | 2015-08-11 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
-
2011
- 2011-12-02 RU RU2013130002/10A patent/RU2013130002A/ru not_active Application Discontinuation
- 2011-12-02 NZ NZ611614A patent/NZ611614A/en not_active IP Right Cessation
- 2011-12-02 CA CA2819679A patent/CA2819679A1/en not_active Abandoned
- 2011-12-02 MX MX2013006116A patent/MX2013006116A/es not_active Application Discontinuation
- 2011-12-02 US US13/990,777 patent/US20140037638A1/en not_active Abandoned
- 2011-12-02 BR BR112013013723A patent/BR112013013723A2/pt not_active IP Right Cessation
- 2011-12-02 JP JP2013542218A patent/JP2014502276A/ja active Pending
- 2011-12-02 WO PCT/US2011/063121 patent/WO2012075422A2/en not_active Ceased
- 2011-12-02 AU AU2011336360A patent/AU2011336360A1/en not_active Abandoned
- 2011-12-02 EP EP11844128.6A patent/EP2646053A4/en not_active Withdrawn
- 2011-12-02 SG SG2013042288A patent/SG190952A1/en unknown
- 2011-12-02 CN CN2011800667946A patent/CN103338786A/zh active Pending
- 2011-12-02 KR KR1020137016719A patent/KR20140017513A/ko not_active Withdrawn
-
2013
- 2013-05-31 ZA ZA2013/03996A patent/ZA201303996B/en unknown
-
2016
- 2016-08-22 US US15/243,495 patent/US20160355581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160355581A1 (en) | 2016-12-08 |
| US20140037638A1 (en) | 2014-02-06 |
| CN103338786A (zh) | 2013-10-02 |
| WO2012075422A2 (en) | 2012-06-07 |
| JP2014502276A (ja) | 2014-01-30 |
| WO2012075422A3 (en) | 2012-10-04 |
| ZA201303996B (en) | 2015-10-28 |
| EP2646053A4 (en) | 2014-05-28 |
| NZ611614A (en) | 2015-07-31 |
| KR20140017513A (ko) | 2014-02-11 |
| EP2646053A2 (en) | 2013-10-09 |
| CA2819679A1 (en) | 2012-06-07 |
| SG190952A1 (en) | 2013-07-31 |
| MX2013006116A (es) | 2013-10-17 |
| BR112013013723A2 (pt) | 2019-09-24 |
| AU2011336360A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013130002A (ru) | Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками | |
| AU2018255221B2 (en) | Anti-N3pGlu amyloid beta peptide antibodies and uses thereof | |
| Huijbers et al. | The expanding field of IgG4‐mediated neurological autoimmune disorders | |
| TW200716677A (en) | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders | |
| AU2011329647B2 (en) | Neutralizing anti-CCL20 antibodies | |
| Antonios et al. | Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X | |
| RU2012141556A (ru) | Способы и композиции для лечения болезни дего | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2014502276A5 (enExample) | ||
| RU2017137872A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2009530423A5 (enExample) | ||
| RU2008137764A (ru) | Способы предотвращения и лечения амилоидных заболеваний | |
| MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2009530299A5 (enExample) | ||
| WO2005103083A8 (en) | Anti-cd38 human antibodies and uses therefor | |
| JP2014524733A5 (enExample) | ||
| RS59557B1 (sr) | Tau antitela i njihova upotreba | |
| NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| WO2023143425A1 (zh) | 改善认知障碍的方法 | |
| RU2010150754A (ru) | АНТИТЕЛА ПРОТИВ PirB | |
| JP2014509860A5 (enExample) | ||
| EA202091629A1 (ru) | Гуманизированные и деиммунизированные антитела | |
| US20230025707A1 (en) | Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same | |
| CA3176743A1 (en) | Use of a.beta.34 to assess alzheimer's disease progression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161114 |